BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17392503)

  • 21. Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site.
    Ladanyi M; Cavalchire G
    Genes Chromosomes Cancer; 1996 Mar; 15(3):173-7. PubMed ID: 8721682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
    Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
    Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
    Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
    Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
    Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
    Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and diagnostic application of genomic
    Krumbholz M; Woessmann W; Zierk J; Seniuk D; Ceppi P; Zimmermann M; Singh VK; Metzler M; Damm-Welk C
    Oncotarget; 2018 May; 9(41):26543-26555. PubMed ID: 29899875
    [No Abstract]   [Full Text] [Related]  

  • 27. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY; Zhao Y; Anderson WF; Johnston PB
    Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.
    Quintanilla-Martinez L; Pittaluga S; Miething C; Klier M; Rudelius M; Davies-Hill T; Anastasov N; Martinez A; Vivero A; Duyster J; Jaffe ES; Fend F; Raffeld M
    Blood; 2006 Sep; 108(6):2029-36. PubMed ID: 16709933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. t(2;5) positive lymphoma with peripheral blood involvement.
    Chhanabhai M; Britten C; Klasa R; Gascoyne RD
    Leuk Lymphoma; 1998 Jan; 28(3-4):415-22. PubMed ID: 9517514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
    Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
    Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
    Gascoyne RD; Lamant L; Martin-Subero JI; Lestou VS; Harris NL; Müller-Hermelink HK; Seymour JF; Campbell LJ; Horsman DE; Auvigne I; Espinos E; Siebert R; Delsol G
    Blood; 2003 Oct; 102(7):2568-73. PubMed ID: 12763927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
    Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
    Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
    Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
    Blood; 2007 Sep; 110(5):1621-30. PubMed ID: 17416736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
    Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
    Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).
    Colleoni GW; Bridge JA; Garicochea B; Liu J; Filippa DA; Ladanyi M
    Am J Pathol; 2000 Mar; 156(3):781-9. PubMed ID: 10702393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
    Rudzki Z; Rucińska M; Jurczak W; Skotnicki AB; Maramorosz-Kurianowicz M; Mruk A; Piróg K; Utych G; Bodzioch P; Srebro-Stariczyk M; Włodarska I; Stachura J
    Pol J Pathol; 2005; 56(1):37-45. PubMed ID: 15921012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
    Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
    Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epstein-Barr virus association and ALK gene expression in anaplastic large-cell lymphoma.
    Agarwal S; Ramanathan U; Naresh KN
    Hum Pathol; 2002 Feb; 33(2):146-52. PubMed ID: 11957137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.
    Gu TL; Tothova Z; Scheijen B; Griffin JD; Gilliland DG; Sternberg DW
    Blood; 2004 Jun; 103(12):4622-9. PubMed ID: 14962911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.